Piper Sandler Lifts Bristol-Myers Squibb Price Target to $75 on Pipeline and Trial Upside
Piper Sandler increased its 12-month price target for Bristol-Myers Squibb to $75 from $66 and reiterated an Overweight rating, pointing to two principal paths the company could use to return to top-line growth after U.S. loss of exclusivity for Eliquis in 2028: a successful milvexian outcome in the LIBREXIA AF atrial fibrillation trial and progres…